Urology

Top Medical News
ADT suppresses levels of several androgen precursor steroids
Tristan Manalac, 7 hours ago
In prostate cancer patients, the initiation of androgen deprivation therapy (ADT) lowers the concentrations of 13 circulating steroids, according to a new study.
Secondary kidney stones: to remove or not?
Audrey Abella, 4 days ago
Pre-emptive removal of secondary* kidney stones during surgery to remove primary** stones led to fewer relapses and a similar number of emergency-department (ED) visits related to the surgery compared with leaving the secondary stones in place, a study suggests.
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Stephen Padilla, 5 days ago
Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.
Active surveillance with delayed intervention a safe, cheaper option for small renal masses
6 days ago
Active surveillance (AS) along with timely delayed intervention (DI) is a safe and economical alternative to immediate intervention in patients with small renal masses (SRM), suggests a study.
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
27 Sep 2022
Some men who undergo artificial urinary sphincter (AUS) and inflatable penile prosthesis (IPP) surgery encounter a venous thromboembolism (VTE) event within 90 days of their operation, reports a study.
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
27 Sep 2022
Treatment with radiotherapy appears to result in more all-cause or prostate cancer-specific mortality (PCSM) compared with radical prostatectomy (RP), suggests a study.
Erectile Dysfunction, ED, Marriage, Relationship, Men health, sex
26 Sep 2022
Sleep parameters are robust predictors of erectile dysfunction (ED), suggesting that poor sleep quality contributes to a greater likelihood of ED, reveals a study.
Special Reports
Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
Conference Reports
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
Roshini Claire Anthony, 25 Aug 2022

Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.

Is 5-year interval sufficient for prostate cancer screening in older men?
Roshini Claire Anthony, 18 Aug 2022

Diagnosis, progression, or death due to prostate cancer occur at approximately a decade to 15 years following an initial assessment of prostate-specific antigen (PSA) levels in older men, according to a study presented at EAU 2022.

Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
Audrey Abella, 08 Aug 2022
The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
Audrey Abella, 04 Aug 2022
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Patients prefer being awake but sedated during urologic procedures
Elvira Manzano, 04 Aug 2022
Patients prefer conscious sedation over general anaesthesia (GA) during urologic procedures, according to Canadian researchers who followed patients undergoing various endourologic, ureteric, urethral, or advanced cystoscopic procedures.
Which drugs raise risk of urinary tract infections?
Stephen Padilla, 29 Jul 2022
Some medications may directly cause the occurrence of urinary tract infections (UTIs), and a recent study presented at the 37th Annual European Association of Urology Congress (EAU 2022) has identified six drugs that appear to contribute to “significant reporting levels” for infections.
SOUNDS: Real-world use affirms efficacy, safety of sacral neuromodulator device for OAB
Jairia Dela Cruz, 28 Jul 2022
Delivering electric stimulation to the sacral nerves using an implantable device appears to be safe and effective in the treatment of overactive bladder (OAB) in a real-world setting, according to the France-based SOUNDS study presented at the 37th Annual European Association of Urology Congress (EAU 2022).